Immunogen (IMGN) Tops Q2 EPS by 21c
Get Alerts IMGN Hot Sheet
EPS Growth %: +100.0%
Financial Fact:
Total operating expenses: 46.5M
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q2 EPS of $0.16, $0.21 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $48.3 million versus the consensus estimate of $37.3 million.
Financial Guidance for Fiscal Year 2015
ImmunoGen’s financial guidance remains unchanged from that issued in October 2014. ImmunoGen expects: its revenues to be between $100 million and $105 million; its operating expenses to be between $160 million and $165 million; its net loss to be between $60 million and $65 million; its cash used in operations to be between $55 million and $60 million; and its capital expenditures to be between $7 million and $9 million. Cash and marketable securities at June 30, 2015 are anticipated to be between $75 million and $85 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Alpine Immune Sciences (ALPN) Reports FY Loss of $0.64
- Eyenovia Inc (EYEN) Misses Q4 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!